Mangrove Partners
TLSIW icon

Mangrove Partners’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Mangrove Partners’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$4.92M – 391
2022
Q2 		$4.92M Hold
500,000
– – 0.24% 130
2022
Q1 		$4.9M Buy
+500,000
New +$215K 0.26% 115

Other funds holding TLSIW

Radcliffe Capital Management
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
Angelo Gordon & Co
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Clear Street
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Vestcor Inc
Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return

Mangrove Partners's TLSIW Position: Q3 2022 in Review

Mangrove Partners sold out of TriSalus Life Sciences Warrant (TLSIW) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.92M sold.

Mangrove Partners first reported a position in TLSIW in Q1 2022 and held it in 2 quarters. The position peaked at $4.92M in Q2 2022. 29 funds tracked by Wall St. Rank hold TLSIW as of Q3 2022.

  • Mangrove Partners reported no remaining TriSalus Life Sciences Warrant position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 500,000 TriSalus Life Sciences Warrant shares in Q3 2022, an estimated $4.92M.
  • Mangrove Partners first reported a position in TriSalus Life Sciences Warrant in Q1 2022 and held it in 2 quarters.
  • Mangrove Partners's TriSalus Life Sciences Warrant position peaked at $4.92M in Q2 2022.
  • 29 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.